About Us

Leading the way to a potential new standard of care for gastrointestinal diseases

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI diseases. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related diseases. We plan to initiate Phase 3 clinical trials for the treatment of erosive GERD and the treatment of H. pylori infection. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.

Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.

Management Team

tachi yamada

Tadataka (Tachi) Yamada, M.D.

Chairman

terrie curran

Terrie Curran

Chief Executive Officer

azmi nabulsi

Azmi Nabulsi, M.D., M.P.H.

Chief Operating Officer

joe hand

Joe Hand

Chief Administrative Officer

tom harris

Tom Harris

Head of Regulatory Affairs

aditya kohli

Aditya Kohli, Ph.D.

Chief Business Officer

eckhard leifke

Eckhard Leifke, M.D.

Chief Medical Officer

larry miller

Larry Miller

General Counsel

david socks

David Socks

Chief Financial Officer

roger ulrich

Roger Ulrich, Ph.D.

Chief Scientific Officer

Board of Directors

Tadataka (Tachi) Yamada, M.D.

Chairman

Terrie Curran

Chief Executive Officer

David Socks

Chief Financial Officer

James Topper, M.D., Ph.D.

Managing General Partner, Frazier Healthcare

Jon Edwards, Ph.D.

Partner, Medicxi

Heidi Kunz

Former CFO, Blue Shield California

Michael Cola

CEO, Aevi Genomic Medicine

Asit Parikh, M.D., Ph.D.

Senior Vice President and Head of the Gastroenterology Therapeutic Area Unit, Takeda